Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer

被引：2
|
作者：
Salomaa, ER [1 ]
Liippo, K [1 ]
Ellmen, J [1 ]
Komi, J [1 ]
机构：
[1] ORION CORP FARMOS,FIN-20101 TURKU,FINLAND
来源：
LUNG CANCER | 1996年 / 16卷 / 01期
关键词：
non-small cell lung cancer; chemotherapy; multi-drug resistance; toremifene; ifosfamide;
D O I：
10.1016/S0169-5002(96)00613-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The efficacy and safety of toremifene-ifosfamide as a first-line chemotherapy in non-small cell lung cancer were assessed. Sixteen patients were treated with oral toremifene (420 mg on days 1-4 and 240 mg on day 5) followed by ifosfamide infusion 5 g/m(2) on day 5 every 3 weeks 1-6 times. Toremifene at the doses used did not enhance the effect or toxicity of ifosfamide in previously untreated non-small cell lung cancer patients. Copyright (C) 1996 Elsevier Science Ireland Ltd.
引用
收藏
页码：75 / 80
页数：6
相关论文
共 50 条
  • [31] Ifosfamide in non-small-cell lung cancer
    Rosell, R
    Martin, C
    Balaña, C
    ANNALS OF ONCOLOGY, 1999, 10 : 25 - 28
  • [32] Pembrolizumab for the treatment of non-small cell lung cancer
    Muller, Mirte
    Schouten, Robert D.
    De Gooijer, Cornedine J.
    Baas, Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (05) : 399 - 409
  • [33] The treatment of advanced non-small cell lung cancer
    Spiro, SG
    Silvestri, GA
    CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (04) : 287 - 291
  • [34] Radiation Treatment of Non-Small Cell Lung Cancer
    Zeng, Jing
    Rengan, Ramesh
    SEMINARS IN RADIATION ONCOLOGY, 2021, 31 (02) : 95 - 96
  • [35] On the pharmacogenetics of non-small cell lung cancer treatment
    Santarpia, Mariacarmela
    Rolfo, Christian
    Peters, G. J.
    Leon, Leticia G.
    Giovannetti, Elisa
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 307 - 317
  • [36] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [37] Aptamers in Non-Small Cell Lung Cancer Treatment
    Wieleba, Irena
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    MOLECULES, 2020, 25 (14):
  • [38] Afatinib for the treatment of non-small cell lung cancer
    Biello, Federica
    Maggioni, Claudia
    Rijavec, Erika
    Genova, Carlo
    Barletta, Giulia
    Gualco, Elisa
    Truini, Anna
    Coco, Simona
    Dal Bello, Maria Giovanna
    Vanni, Irene
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1357 - 1364
  • [39] Personalized treatment in non-small cell lung cancer
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2012, 64 (04): : 377 - 386
  • [40] Targeted treatment of non-small cell lung cancer
    Scheffler, Matthias
    Michels, Sebastian
    Nogova, Lucia
    INNERE MEDIZIN, 2022, 63 (07): : 700 - 708
12345